Stockscreener 앱 받기
9.98
8.95%
0.82
시간 외 거래:
9.79
-0.19
-1.90%
전일 마감가:
$9.16
열려 있는:
$9.51
하루 거래량:
543.99K
Relative Volume:
4.05
시가총액:
$3.38B
수익:
$417.75M
순이익/손실:
$32.27M
주가수익비율:
102.36
EPS:
0.0975
순현금흐름:
-
1주 성능:
+8.36%
1개월 성능:
-11.68%
6개월 성능:
-43.30%
1년 성능:
+0.00%
1일 변동 폭
$9.51
$10.00
1주일 범위
$9.15
$10.00
52주 변동 폭
$8.93
$30.36
Telix Pharmaceuticals Ltd Adr Stock (TLX) Company Profile
TLX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TLX
Telix Pharmaceuticals Ltd Adr
|
9.98 | 3.07B | 417.75M | 32.27M | 0 | 0.0975 |
|
VRTX
Vertex Pharmaceuticals Inc
|
383.12 | 99.25B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
591.99 | 63.46B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.56 | 59.27B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
736.76 | 44.78B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
334.40 | 37.75B | 3.81B | -644.79M | -669.77M | -6.24 |
Telix Pharmaceuticals Ltd Adr Stock (TLX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-18 | 개시 | Citigroup | Buy |
| 2025-08-28 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2025-07-03 | 개시 | H.C. Wainwright | Buy |
| 2025-06-05 | 개시 | Wedbush | Outperform |
| 2024-11-15 | 개시 | UBS | Buy |
Telix Pharmaceuticals Ltd Adr 주식(TLX)의 최신 뉴스
TLX Investor News: If You Have Suffered Losses in Telix Pharmaceuticals Ltd. (NASDAQ: TLX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights - GlobeNewswire Inc.
TLX Investor News: If You Have Suffered Losses in Telix - GlobeNewswire
Rosen Law Firm Encourages Telix Pharmaceuticals Ltd. Investors to Inquire About Securities Class Action InvestigationTLX - cnhinews.com
TELIX ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
About Us - FinancialContent
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals LimitedTLX - cnhinews.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited – TLX - Morningstar
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited – TLX | Salt Lake City News, Weather, Sports, Breaking News | KUTV - FinancialContent
Telix stock plunges after FDA issues Complete Response Letter - Investing.com
Telix stock plunges after FDA issues Complete Response Letter By Investing.com - Investing.com Nigeria
Telix Shares Drop After FDA Issues Complete Response Letter - MSN
TLX Investors Have Opportunity to Join Telix Pharmaceuticals Limited Fraud Investigation with the Schall Law Firm - Barchart.com
Telix Pharmaceuticals faces SEC subpoena, investors encouraged to contact Bragar Eagel & Squire. - AInvest
TELIX ALERT: Bragar Eagel & Squire, P.C. is Investigating Telix Pharmaceuticals Limited on Behalf of Telix Stockholders and Encourages Investors to Contact the Firm - Morningstar
Investigation into Telix Pharmaceuticals Ltd. Allegations of Misleading Business Information - AInvest
Rosen Law Firm Encourages Telix Pharmaceuticals Ltd. Investors to Inquire About Securities Class Action Investigation – TLX - Business Wire
Telix Pharmaceuticals under SEC investigation, shareholder lawsuit launched. - AInvest
Regulatory Scrutiny and Biotech Volatility: Lessons from Telix Pharmaceuticals' SEC Subpoena - AInvest
Telix Pharmaceuticals under SEC investigation for securities fraud, shares plummet. - AInvest
Telix Pharmaceuticals Under Investigation for Securities Fraud and Misconduct. - AInvest
Pomerantz LLP investigates Telix Pharmaceuticals on securities fraud claims. - AInvest
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited – TLX - FinancialContent
Telix Pharmaceuticals under investigation for potential securities fraud. - AInvest
Bronstein, Gewirtz & Grossman, LLC Is Investigating Telix Pharmaceuticals Limited (TLX) And Encourages Shareholders to Connect - ACCESS Newswire
Telix Pharmaceuticals Limited (TLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Telix Pharmaceuticals under investigation for securities fraud, ADR price falls. - AInvest
Telix Pharmaceuticals Limited (TLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Telix Pharmaceuticals Limited (TLX) And Encourages Investors to Connect - ACCESS Newswire
Telix Pharmaceuticals under investigation for alleged securities fraud. - AInvest
Bronstein, Gewirtz & Grossman, LLC Encourages Telix Pharmaceuticals Limited (TLX) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Telix Announces H1 2025 Earnings Date: Global Investors Briefing Set for August 21 - Stock Titan
Telix Pharmaceuticals Limited (TLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Telix Pharmaceuticals Limited (TLX) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals LimitedTLX - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Telix Pharmaceuticals Limited (TLX) Investors to Inquire about Securities Investigation - ACCESS Newswire
Telix Pharma slides 10% on SEC probe into cancer treatment - Investing.com
Telix Earnings Report: $204M Revenue Crushes Estimates as New Drug Launch Boosts Growth - Stock Titan
Medicare Grants Crucial Reimbursement Code for Telix's Next-Gen Prostate Cancer Imaging Agent - Stock Titan
Telix Pharmaceuticals Ltd Adr (TLX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.43%
0.09%
자본화:
|
볼륨(24시간):